3.4.2 Allergen immunotherapy

Bee and wasp allergen extracts

Pharmalgen®
  • Bee venom extract
  • Wasp venom extract

Notes

  1. NICE TA246: Pharmalgen® isrecommended as an option for the treatment of IgE-mediated bee and waspvenom allergy in people who have had a severe systemicreaction to bee or wasp venom, or, a moderate systemic reaction to bee or waspvenom and who have one or more of the following: a raised baseline serumtryptase, a high risk of future stings or anxiety about future stings. (February 2012)

Grass pollen extract

Grazax®
  • Oral lyophilisates 75,000 units (£74.78)

Indications

  • Seasonal allergic hay fever due to grass or tree pollen in patients who have failed to respond to anti-allergy drugs

Dose

  • Adult and child over 5 years, 1 tablet daily; start treatment at least 4 months before start of pollen season

Notes

  1. Treatment with Grazax® will not be continued longer than 3 years.
  2. Consultant initiated

Benralizumab

Benralizumab
  • Solution for injection in pre-filled syringes 30mg/1ml

Notes

  1. NICE TA565: Benralizumab (Fasenra), as an add-on therapy, is recommended as an option for treating severe eosinophilic asthma that is inadequately controlled in adults despite maintenance therapy with high-dose inhaled corticosteroids and long-acting beta-agonists, only when the criteria of the NICE TA are met (March 2019)
  2. If benralizumab, mepolizumab or reslizumab are equally suitable, start treatment with the least expensive option (taking into account drug and administration costs)

Mepolizumab

Mepolizumab
  • Powder for solution for injection vial 100mg

Notes

  1. NICE TA671: Mepolizumab (Nucala), as an add-on therapy, is recommended as an option for treating severe refractory eosinophilic asthma, only when the criteria of the NICE TA are met (February 2021)
  2. If mepolizumab, benralizumab or reslizumab are equally suitable, start treatment with the least expensive option (taking into account drug and administration costs)

Omalizumab

Omalizumab
  • Solution for injection in pre-filled syringes 150mg/1ml, 75mg/0.5ml

Notes

  1. NICE TA278: Omalizumab (Xolair) is recommended as an option for treating severe persistent confirmed allergic IgE mediated asthma as an add on to optimised standard therapy in people aged 6 years and older, only when the criteria of the NICE TA are met (April 2013)
  2. NICE TA339: Omalizumab (Xolair) is recommended as an option as add on therapy for treating severe chronic spontaneous urticaria in adults and young people aged 12 years and over, only when the criteria of the NICE TA are met (June 2015)
  3. MHRA Drug Safety Update (February 2011): Use of omalizumab may be associated with an increased risk of arterial thrombotic events. Prescribers should be vigilant for possible thrombotic adverse reactions.

Reslizumab

Reslizumab
  • Concentrate for solution for infusion vial 100mg/10ml, 25mg/2.5ml

Notes

  1. NICE TA479: Reslizumab (Cinqaero), as an add-on therapy, is recommended as an option for the treatment of severe eosinophilic asthma that is inadequately controlled in adults despite maintenance therapy with high-dose inhaled corticosteroids plus another drug, only when the criteria of the NICE TA are met (October 2017)


 

Home > Formulary > Chapters > 3. Respiratory > 3.4 Antihistamines, hyposensitisation, and allergic emergencies > 3.4.2 Allergen immunotherapy

 

  • First line
  • Second line
  • Specialist
  • Hospital